King's College London

Research portal

Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies

Research output: Contribution to journalReview article

Standard

Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies. / Brunckhorst, Oliver; Hashemi, Safiya; Martin, Anastasia; George, Gincy; Van Hemelrijck, Mieke; Dasgupta, Prokar; Stewart, Robert; Ahmed, Kamran.

In: PROSTATE CANCER AND PROSTATIC DISEASES, 25.09.2020.

Research output: Contribution to journalReview article

Harvard

Brunckhorst, O, Hashemi, S, Martin, A, George, G, Van Hemelrijck, M, Dasgupta, P, Stewart, R & Ahmed, K 2020, 'Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies', PROSTATE CANCER AND PROSTATIC DISEASES. https://doi.org/10.1038/s41391-020-00286-0

APA

Brunckhorst, O., Hashemi, S., Martin, A., George, G., Van Hemelrijck, M., Dasgupta, P., Stewart, R., & Ahmed, K. (2020). Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies. PROSTATE CANCER AND PROSTATIC DISEASES. https://doi.org/10.1038/s41391-020-00286-0

Vancouver

Brunckhorst O, Hashemi S, Martin A, George G, Van Hemelrijck M, Dasgupta P et al. Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies. PROSTATE CANCER AND PROSTATIC DISEASES. 2020 Sep 25. https://doi.org/10.1038/s41391-020-00286-0

Author

Brunckhorst, Oliver ; Hashemi, Safiya ; Martin, Anastasia ; George, Gincy ; Van Hemelrijck, Mieke ; Dasgupta, Prokar ; Stewart, Robert ; Ahmed, Kamran. / Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies. In: PROSTATE CANCER AND PROSTATIC DISEASES. 2020.

Bibtex Download

@article{819041a8eced4c23b7517571ab9c9126,
title = "Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies",
abstract = "Background: Psychiatric implications of prostate cancer are increasingly recognised, having important effects on oncological and functional outcomes. However, findings for co-occurring depression, anxiety, and suicidality remain variable. Therefore, this review of observational studies aimed to establish best estimates of the prevalence and rates of these outcomes in prostate cancer patients. Methods: A systematic literature search was conducted using MEDLINE, Scopus, PsycInfo, and Cochrane Library databases from inception up to 26 May 2020. Observational studies using validated methods for evaluating prevalences of depression, anxiety and suicidal ideation, or suicide mortality rates post prostate cancer diagnosis were included. Random effect models were used to calculate pooled prevalences of depressive and anxiety symptoms or disorders, and suicidal ideation post diagnosis. Additionally, pooled crude suicide mortality rates per 100,000 person years were calculated. Heterogeneity was explored using a stratified analysis. Results: Of 3537 articles screened, 117 were included. Pooled prevalence for depressive disorders was 5.81% (95% CI 4.36–7.46) in 11 studies, representing 655,149 patients. Significant depressive symptoms were identified in 17.07% (15.14–19.09) across 32,339 patients and 76 studies. In total, 16.86% (14.92–18.89) had significant anxiety symptoms in 56 studies combining 24,526 patients. In 6,173 patients and eight studies, recent suicidal ideation was present in 9.85% (7.31–12.70). Crude suicide mortality rate after diagnosis was 47.1 (39.85–54.96) per 100,000 person years in 12 studies. Significant heterogeneity was seen with potential sources identified through our sensitivity analysis including diagnostic method utilised, study size and location of study. Conclusions: The mental health impact in patients with prostate cancer is significant. Depressive, anxiety, and suicidal symptoms were common. Additionally, a high suicide mortality rate was identified when compared to general population estimates. Screening of patients and integration of physical and mental health care should be evaluated further to improve quality of life and functional outcomes.",
author = "Oliver Brunckhorst and Safiya Hashemi and Anastasia Martin and Gincy George and {Van Hemelrijck}, Mieke and Prokar Dasgupta and Robert Stewart and Kamran Ahmed",
year = "2020",
month = sep,
day = "25",
doi = "10.1038/s41391-020-00286-0",
language = "English",
journal = "PROSTATE CANCER AND PROSTATIC DISEASES",
issn = "1365-7852",
publisher = "Nature Publishing Group",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies

AU - Brunckhorst, Oliver

AU - Hashemi, Safiya

AU - Martin, Anastasia

AU - George, Gincy

AU - Van Hemelrijck, Mieke

AU - Dasgupta, Prokar

AU - Stewart, Robert

AU - Ahmed, Kamran

PY - 2020/9/25

Y1 - 2020/9/25

N2 - Background: Psychiatric implications of prostate cancer are increasingly recognised, having important effects on oncological and functional outcomes. However, findings for co-occurring depression, anxiety, and suicidality remain variable. Therefore, this review of observational studies aimed to establish best estimates of the prevalence and rates of these outcomes in prostate cancer patients. Methods: A systematic literature search was conducted using MEDLINE, Scopus, PsycInfo, and Cochrane Library databases from inception up to 26 May 2020. Observational studies using validated methods for evaluating prevalences of depression, anxiety and suicidal ideation, or suicide mortality rates post prostate cancer diagnosis were included. Random effect models were used to calculate pooled prevalences of depressive and anxiety symptoms or disorders, and suicidal ideation post diagnosis. Additionally, pooled crude suicide mortality rates per 100,000 person years were calculated. Heterogeneity was explored using a stratified analysis. Results: Of 3537 articles screened, 117 were included. Pooled prevalence for depressive disorders was 5.81% (95% CI 4.36–7.46) in 11 studies, representing 655,149 patients. Significant depressive symptoms were identified in 17.07% (15.14–19.09) across 32,339 patients and 76 studies. In total, 16.86% (14.92–18.89) had significant anxiety symptoms in 56 studies combining 24,526 patients. In 6,173 patients and eight studies, recent suicidal ideation was present in 9.85% (7.31–12.70). Crude suicide mortality rate after diagnosis was 47.1 (39.85–54.96) per 100,000 person years in 12 studies. Significant heterogeneity was seen with potential sources identified through our sensitivity analysis including diagnostic method utilised, study size and location of study. Conclusions: The mental health impact in patients with prostate cancer is significant. Depressive, anxiety, and suicidal symptoms were common. Additionally, a high suicide mortality rate was identified when compared to general population estimates. Screening of patients and integration of physical and mental health care should be evaluated further to improve quality of life and functional outcomes.

AB - Background: Psychiatric implications of prostate cancer are increasingly recognised, having important effects on oncological and functional outcomes. However, findings for co-occurring depression, anxiety, and suicidality remain variable. Therefore, this review of observational studies aimed to establish best estimates of the prevalence and rates of these outcomes in prostate cancer patients. Methods: A systematic literature search was conducted using MEDLINE, Scopus, PsycInfo, and Cochrane Library databases from inception up to 26 May 2020. Observational studies using validated methods for evaluating prevalences of depression, anxiety and suicidal ideation, or suicide mortality rates post prostate cancer diagnosis were included. Random effect models were used to calculate pooled prevalences of depressive and anxiety symptoms or disorders, and suicidal ideation post diagnosis. Additionally, pooled crude suicide mortality rates per 100,000 person years were calculated. Heterogeneity was explored using a stratified analysis. Results: Of 3537 articles screened, 117 were included. Pooled prevalence for depressive disorders was 5.81% (95% CI 4.36–7.46) in 11 studies, representing 655,149 patients. Significant depressive symptoms were identified in 17.07% (15.14–19.09) across 32,339 patients and 76 studies. In total, 16.86% (14.92–18.89) had significant anxiety symptoms in 56 studies combining 24,526 patients. In 6,173 patients and eight studies, recent suicidal ideation was present in 9.85% (7.31–12.70). Crude suicide mortality rate after diagnosis was 47.1 (39.85–54.96) per 100,000 person years in 12 studies. Significant heterogeneity was seen with potential sources identified through our sensitivity analysis including diagnostic method utilised, study size and location of study. Conclusions: The mental health impact in patients with prostate cancer is significant. Depressive, anxiety, and suicidal symptoms were common. Additionally, a high suicide mortality rate was identified when compared to general population estimates. Screening of patients and integration of physical and mental health care should be evaluated further to improve quality of life and functional outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85091509195&partnerID=8YFLogxK

U2 - 10.1038/s41391-020-00286-0

DO - 10.1038/s41391-020-00286-0

M3 - Review article

JO - PROSTATE CANCER AND PROSTATIC DISEASES

JF - PROSTATE CANCER AND PROSTATIC DISEASES

SN - 1365-7852

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454